192 related articles for article (PubMed ID: 25486403)
1. Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.
Aletraris L; Bond Edmond M; Roman PM
J Stud Alcohol Drugs; 2015 Jan; 76(1):143-51. PubMed ID: 25486403
[TBL] [Abstract][Full Text] [Related]
2. Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector.
Abraham AJ; Roman PM
J Stud Alcohol Drugs; 2010 May; 71(3):460-6. PubMed ID: 20409441
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
Koch AL; Arfken CL; Schuster CR
Drug Alcohol Depend; 2006 Jul; 83(3):274-8. PubMed ID: 16413146
[TBL] [Abstract][Full Text] [Related]
4. A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation.
Abraham AJ; Knudsen HK; Roman PM
J Stud Alcohol Drugs; 2011 Jul; 72(4):669-77. PubMed ID: 21683049
[TBL] [Abstract][Full Text] [Related]
5. State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder.
Abraham AJ; Andrews CM; Grogan CM; Pollack HA; D'Aunno T; Humphreys K; Friedmann PD
Psychiatr Serv; 2018 Apr; 69(4):448-455. PubMed ID: 29241428
[TBL] [Abstract][Full Text] [Related]
6. Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach.
Abraham AJ; Rieckmann T; McNulty T; Kovas AE; Roman PM
Addict Behav; 2011 Jun; 36(6):576-583. PubMed ID: 21382667
[TBL] [Abstract][Full Text] [Related]
7. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
[TBL] [Abstract][Full Text] [Related]
8. Adoption and implementation of medications in addiction treatment programs.
Knudsen HK; Abraham AJ; Roman PM
J Addict Med; 2011 Mar; 5(1):21-7. PubMed ID: 21359109
[TBL] [Abstract][Full Text] [Related]
9. Adoption of naltrexone to treat alcohol dependence.
Fuller BE; Rieckmann T; McCarty D; Smith KW; Levine H
J Subst Abuse Treat; 2005 Apr; 28(3):273-80. PubMed ID: 15857728
[TBL] [Abstract][Full Text] [Related]
10. Extended-Release Naltrexone for Alcohol and Opioid Problems in Missouri Parolees and Probationers.
Crits-Christoph P; Lundy C; Stringer M; Gallop R; Gastfriend DR
J Subst Abuse Treat; 2015 Sep; 56():54-60. PubMed ID: 25841704
[TBL] [Abstract][Full Text] [Related]
11. A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.
Crits-Christoph P; Markell HM; Gibbons MB; Gallop R; Lundy C; Stringer M; Gastfriend DR
J Subst Abuse Treat; 2016 Nov; 70():50-57. PubMed ID: 27692188
[TBL] [Abstract][Full Text] [Related]
12. Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use.
Alanis-Hirsch K; Croff R; Ford JH; Johnson K; Chalk M; Schmidt L; McCarty D
J Subst Abuse Treat; 2016 Mar; 62():68-73. PubMed ID: 26654934
[TBL] [Abstract][Full Text] [Related]
13. Provision of onsite HIV Services in Substance Use Disorder Treatment Programs: A Longitudinal Analysis.
Aletraris L; Roman PM
J Subst Abuse Treat; 2015 Oct; 57():1-8. PubMed ID: 25934459
[TBL] [Abstract][Full Text] [Related]
14. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs.
Friedmann PD; Jiang L; Alexander JA
J Behav Health Serv Res; 2010 Jul; 37(3):322-37. PubMed ID: 19296223
[TBL] [Abstract][Full Text] [Related]
15. A demonstration project implementing extended-release naltrexone in Los Angeles County.
Cousins SJ; Denering L; Crèvecoeur-MacPhail D; Viernes J; Sugita W; Barger J; Kim T; Weimann S; Rawson RA
Subst Abus; 2016; 37(1):54-62. PubMed ID: 26158698
[TBL] [Abstract][Full Text] [Related]
16. The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters.
Knudsen HK; Ducharme LJ; Roman PM
Drug Alcohol Depend; 2007 Mar; 87(2-3):164-74. PubMed ID: 16971059
[TBL] [Abstract][Full Text] [Related]
17. Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders.
Knudsen HK; Roman PM
J Stud Alcohol Drugs; 2014 May; 75(3):467-75. PubMed ID: 24766759
[TBL] [Abstract][Full Text] [Related]
18. Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.
Gordon MS; Vocci FJ; Fitzgerald TT; O'Grady KE; O'Brien CP
Contemp Clin Trials; 2017 Feb; 53():130-136. PubMed ID: 28011389
[TBL] [Abstract][Full Text] [Related]
19. Medicaid coverage of medications to treat alcohol and opioid dependence.
Mark TL; Lubran R; McCance-Katz EF; Chalk M; Richardson J
J Subst Abuse Treat; 2015 Aug; 55():1-5. PubMed ID: 25921475
[TBL] [Abstract][Full Text] [Related]
20. Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.
Uebelacker LA; Bailey G; Herman D; Anderson B; Stein M
J Subst Abuse Treat; 2016 Jul; 66():48-53. PubMed ID: 27211996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
